- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04487431
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
Single-center, Open-label, Non-placebo-controlled, Single-dose Study in Healthy Male Participants to Determine the Pharmacokinetics of BAY 1817080 Oral Solution (Part A) and to Investigate the Pharmacokinetics, Metabolic Disposition and Mass Balance of [14C]BAY 1817080 Oral Solution (Part B)
Researchers are looking for a new way to treat people suffering either from a condition where the bladder is unable to hold urine normally (overactive bladder), or a condition in which tissue similar to the tissue that normally lines the inside of the womb grows outside the womb (endometriosis) or a condition where the cough lasts longer than 8 weeks in adults (chronic cough). BAY1817080 is a new drug that is in development as a potential treatment for these conditions.
In this trial, the researchers want to learn how a new liquid form of BAY1817080 is taken up by the body in a small number of healthy participants. The trial will include men who are aged 18 to 54.
The trial will have 2 parts: A and B. The participants in Part A will stay at the trial site for about 5 days. During this time, the participants will take 1 dose of a liquid form of BAY1817080 by mouth. The doctors will take blood and urine samples and check the participants' health. Part A will be done so the researchers can see how much BAY1817080 gets into the participants' blood. The participants in Part B will stay at the trial site for about 16 days followed by a maximum of 4 re-admission visits over 24 hours at intervals of 7 days. These participants will take 1 dose of a liquid form of BAY1817080 labeled with a radioactive substance (carbon 14), which means it is "radiolabeled". This allows the researchers to understand how BAY1817080 moves through and leaves the body. During Part B, the doctors will take blood, urine, stool, and vomit samples if applicable. They will also check the participants' health.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9728 NZ
- Prahealthsciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Capable of giving signed informed consent as described in Appendix which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol;
- Ability to understand and follow study-related instructions;
- Participant has signed the ICF before any study specific tests or procedures are done;
- Healthy male participant;
- Age: 18 to 54 years (inclusive) at the time of informed consent and first dose of study medication;
- Body mass index (BMI) ≥18 and ≤30 kg/m^2 at Screening;
- Body weight of at least 45 kg at Screening;
- Participant agrees to use contraception as described in Appendix.
Exclusion Criteria:
- Presence or history of clinically relevant cardiovascular, central nervous system (CNS), hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash;
- Known hypersensitivity to the study drugs (active substances or excipients of the preparations);
- Known severe allergies, e.g., allergies to more than 3 allergens, allergies affecting the lower respiratory tract (e.g., allergic asthma), allergies requiring therapy with corticosteroids or significant nonallergic drug reactions;
- Febrile illness within 1 week before study drug administration;
- Current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (i.e., a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent occurrence of heartburn [more than once per week], or any gastrointestinal surgical intervention [e.g. cholecystectomy]);
- Participant has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Screening;
- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of study intervention will not be normal;
- Poor peripheral venous access;
- Regular use of medicines within 14 days prior to administration of study intervention;
- Regular use of therapeutic or recreational drugs, e.g., cannabis, carnitine products, anabolics, high dose vitamins within 3 months prior to screening;
- Any use of medicines or substances within 14 days prior to administration, which oppose the study objectives or might affect the PK of BAY1817080 (e.g., laxatives, loperamide, metoclopramide, antacids, H2-receptor antagonists, systemic antibiotics, CYP3A4 inducers, CYP3A4 inhibitors, "organic anion transporting polypeptide" (OATP) / "breast cancer resistance protein" (BCRP) substrates, P-gp substrates and inhibitors). Relevant medication of individual participants will be discussed with the study medical expert before first dosing in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAY1817080 Part A
Healthy male participants will receive BAY1817080 given as an oral solution (study Part A)
|
Oral single dose
|
Experimental: [14C]BAY1817080 Part B
Healthy male participants will receive BAY1817080 blended with [14C]BAY1817080 given as an oral solution (study Part B).
|
Oral single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC of BAY1817080 in plasma (Part A)
Time Frame: Pre-dose, post-dose on Day 1 (up to 16 hours), Days 2 to 4 (every 12 hours)
|
Area under the concentration vs. time curve
|
Pre-dose, post-dose on Day 1 (up to 16 hours), Days 2 to 4 (every 12 hours)
|
Maximum observed concentration of BAY1817080 in plasma (Cmax) (Part A)
Time Frame: Pre-dose, post-dose on Day 1 (up to 16 hours), Days 2 to 4 (every 12 hours)
|
Pre-dose, post-dose on Day 1 (up to 16 hours), Days 2 to 4 (every 12 hours)
|
|
Radioactivity excreted in urine of BAY1817080 and its metabolites as a percentage of the dose (%AE,ur) (Part B)
Time Frame: Pre-dose, Day 1 (0-12 h and 12-24 h), Days 2 to 15, 22, 29, 36, 43
|
Pre-dose, Day 1 (0-12 h and 12-24 h), Days 2 to 15, 22, 29, 36, 43
|
|
Radioactivity excreted in feces of BAY1817080 and its metabolites as a percentage of the dose (%AE,fec) (Part B)
Time Frame: Pre-dose, Days 1 to 15, 22, 29, 36, 43
|
Pre-dose, Days 1 to 15, 22, 29, 36, 43
|
|
Radioactivity excreted in vomit (if applicable) of BAY1817080 and its metabolites as a percentage of the dose (%AE,v) (Part B)
Time Frame: Up to 12 hours post-dose
|
Up to 12 hours post-dose
|
|
AUC of total radioactivity (Part B)
Time Frame: Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15, 22, 29, 36, 43
|
Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15, 22, 29, 36, 43
|
|
Cmax of total radioactivity (Part B)
Time Frame: Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15, 22, 29, 36, 43
|
Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15, 22, 29, 36, 43
|
|
Whole blood to plasma ratio of total radioactivity (Part B)
Time Frame: Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15, 22, 29, 36, 43
|
Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15, 22, 29, 36, 43
|
|
AUC of [14C]BAY1817080 in Plasma (Part B)
Time Frame: Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15
|
Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15
|
|
Cmax of [14C]BAY1817080 in plasma (Part B)
Time Frame: Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15
|
Pre-dose, post-dose on Day 1 (up to 12 hours), Days 2 to 10, 12, 15
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with TEAEs (Part B)
Time Frame: From first dose up to Day 15
|
From first dose up to Day 15
|
Number of participants with Treatment-emergent adverse events (TEAEs) (Part A)
Time Frame: From first dose up to Day 15
|
From first dose up to Day 15
|
Number of participants with maximum severity of TEAEs (Part A)
Time Frame: From first dose up to Day 15
|
From first dose up to Day 15
|
Number of participants with maximum severity of TEAEs (Part B)
Time Frame: From first dose up to Day 15
|
From first dose up to Day 15
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20330
- 2020-000519-54 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on BAY1817080
-
BayerCompletedOveractive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic CoughUnited States
-
BayerCompletedRefractory and/or Unexplained Chronic CoughBelgium, Taiwan, Australia, Netherlands, Spain, Japan, United States, Germany, Turkey, United Kingdom, Argentina, Italy, Slovakia, Hungary, France, Canada, Czechia, Poland, Russian Federation
-
BayerTerminatedEndometriosisSpain, Belgium, United States, Germany, Austria, Japan, Canada, Hungary, Bulgaria, Italy, China, Czechia, Finland, Norway, Poland, Slovakia, Estonia, Greece, Latvia, Lithuania
-
BayerCompletedBiological AvailabilityNetherlands
-
BayerCompletedOveractive BladderAustria, Singapore, New Zealand, Australia, Portugal, Czechia, Poland, Germany, Sweden
-
BayerCompleted
-
BayerCompleted
-
BayerCompletedOveractive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic CoughJapan
-
BayerTerminatedNeuropathic Pain Associated With Diabetic Peripheral NeuropathyGermany, Denmark, France, Poland, Finland, Czechia, Hungary, Norway, Slovakia, Sweden
-
BayerCompletedOveractive Bladder | Cough | EndometriosisGermany